New Director of Science Strategy, Dr Mathew Vadas AO, joins HRI
HRI welcomes Dr Mathew Vadas AO as Director of Science Strategy. Dr Vadas is an internationally renowned immunologist and research leader.
PhD student Alexander Lin publishes collaborative review on atherosclerosis research
The HRI Atherosclerosis and Vascular Remodelling Group has published a paper on how cardiovascular diseases are linked to clonal expansion in JACC: Basic to Translational Science.
HRI breaking new ground in stroke research and care
Assoc Prof Simone Schoenwaelder publishes an update on the exciting advancements in stroke research at HRI that could help stroke patients.
Revolutionising new treatment options for stroke
HRI has been awarded an almost $1 million Cardiovascular Research Capacity Program grant to revolutionise treatment options for stroke.
Thrombosis Group awarded OHMR Award
The Thrombosis Group at HRI has been awarded an OHMR award for a PhD Scholarship. The award will support PhD student Cameron Trought in stroke research.
Dr Jessica Maclean awarded Hillcrest Foundation grant to fight stroke
Dr Jessica Maclean has been awarded a grant from the Hillcrest Foundation for research that seeks to revolutionise stroke therapy.
World-first clinical trials begin for promising new anti-clotting stroke drug
HRI has made a breakthrough 25 years in the making, identifying and developing a new anti-clotting drug that shows great promise in the treatment of stroke.
World first: risk of dementia linked to high cholesterol
HRI has made a world-first breakthrough discovery, linking high cholesterol with an increased risk of dementia for the first time.
Pioneering cardiovascular disease research enabling personalised medical treatment
HRI is using innovative fluxomics technology to identify and explore the cell molecular fingerprint unique to each person's cardiovascular disease, with the goal of personalised medicine.